Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group determined that adding bevacizumab to initial treatment for glioblastoma did not improve patient overall survival or progression-free survival. Results appear in the Feb. 20, 2014, issue of the New England Journal of Medicine.
↧